A new regulatory filing revealed that Synthorx received a sweeter offer than Sanofi’s $2.5 billion bid after the biotech had already agreed to the French pharma’s proposal. The biotech declined to backtrack on accepting Sanofi’s...

Sanofi’s deal for Synthorx shows its continued commitment to building an innovative pipeline in oncology, an area of increasing importance to the pharma, by obtaining both a clinical program targeting IL-2 and a platform it...

Seven of the 10 investors in Cleave Therapeutics' existing syndicate have agreed to recapitalize the company with a new $12 million round, with which Cleave will test a second-generation cancer compound following a toxicity snag...

Synthorx Inc. is poised to enter the clinic this year with an IL-2 therapy that could validate its synthetic DNA platform. Marrying its click chemistry and unnatural amino acid technology with pegylation, the company is...

Synthetic biology company Synthorx Inc. (La Jolla, Calif.) hired Laura Shawver as president, CEO and a director. She was CEO of Cleave Biosciences Inc. (Burlingame, Calif.). Vir Biotechnology Inc. (San Francisco, Calif.) hired Herbert “Skip”...

Autoimmune and inflammatory disease company Akari Therapeutics plc (NASDAQ:AKTX) named David Horn Solomon CEO, effective Aug. 28. He was managing partner at Sund Capital, and was previously CEO of Zealand Pharma A/S (CSE:ZEAL; NASDAQ:ZEAL) and...

Scientists led by Caltech’s Raymond Deshaies have published a first-in-class proteasome inhibitor that acts through a distinct mechanism from the multiple myeloma drugs Velcade bortezomib and Kyprolis carfilzomib, which could address patients who don't respond...

Genomic profiling company Foundation Medicine Inc. (NASDAQ:FMI) said Troy Cox will replace Michael Pellini as CEO, effective Feb. 6. Pellini will remain chairman. Cox was SVP in bio-oncology sales and marketing at the Genentech Inc....

Cleave Biosciences Inc. has steered clear of non-dilutive partnership dollars in hopes of internally validating the profile of its first-in-class cancer therapeutic CB-5083 . Now, the biotech has attracted a cadre of new investors in last...

Cleave Biosciences Inc. , Burlingame, Calif.   Business: Cancer   Date completed: 2016-08-08   Type: Venture financing   Raised: $37 million   Investors: Celgene Corp. ; Nextech Invest; Arcus Ventures; 5AM Ventures; Clarus ; New Enterprise...